Orelabrutinib
Primary Immune Thrombocytopenia (ITP)
Key Facts
About Zenas BioPharma
Zenas BioPharma is a clinical-stage biopharma company focused on developing and commercializing therapies for autoimmune diseases. Its strategy centers on acquiring and advancing late-stage assets with validated mechanisms, such as the bifunctional antibody obexelimab and the BTK inhibitor orelabrutinib, to address large market opportunities. The company is led by an experienced team with a proven track record in drug development and commercialization, operating with a patient-centric mission and a sense of urgency.
View full company profileAbout Zenas BioPharma
Zenas BioPharma is a clinical-stage biopharma company focused on developing and commercializing therapies for autoimmune diseases. Its strategy centers on acquiring and advancing late-stage assets with validated mechanisms, such as the bifunctional antibody obexelimab and the BTK inhibitor orelabrutinib, to address large market opportunities. The company is led by an experienced team with a proven track record in drug development and commercialization, operating with a patient-centric mission and a sense of urgency.
View full company profileTherapeutic Areas
Other Primary Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| HDM1002 (Sovleplenib) | Huadong Medicine (HD Medicine) | NDA Submitted |
| Efgartigimod | Argenx | Approved |
| Sovleplenib (HMPL-523) | HUTCHMED | Phase III |